Fees payable to the European Agency for the Evaluation of Medicinal Products

In adopting the report by Mr Michael TAPPIN (PSE, UK) on the European Agency for the Evaluation of Medicinal Products, the European Parliament adopted a number of amendments to render more stringent the obligation to consult Parliament about the fees payable to the Agency. The general principle of own resources is recalled, and the link between the Agency's resources and the EU budget is confirmed (Parliament particularly stresses that the fees charged by the Agency must be regarded as Community revenue and entered in the budget as preallocated resources for the Agency). Parliament seeks to give the Agency the flexibility it needs as regards the granting of EU funds. �